Nephronomics, an AI-bio precision medicine company focused on transforming cardio-kidney-metabolic disease care, has received an investment from CerraCap Ventures to accelerate the development of its data-driven healthcare platform. The investment will support Nephronomics’ efforts to use artificial intelligence, genomic information, and clinical data to identify disease subtypes, discover therapeutic targets, and advance precision medicine approaches for kidney-related conditions.

Nephronomics is building a vertically integrated precision medicine platform centered around cardio-kidney-metabolic (CKM) diseases, a group of interconnected conditions involving cardiovascular, kidney, and metabolic disorders. The company combines clinical data, genomic information, machine learning models, and computational biology tools to develop insights aimed at improving diagnosis, patient stratification, and therapeutic discovery.

The investment from CerraCap Ventures reflects the venture firm’s interest in healthcare technology companies using artificial intelligence and data analytics to address complex medical challenges. CerraCap Ventures focuses on early-stage technology investments, particularly companies developing solutions in healthcare, cybersecurity, and enterprise technology. Through its investment in Nephronomics, CerraCap is supporting the company’s mission to create new approaches for understanding and treating chronic kidney and related diseases.

Founded as a joint venture between Mechanica Partners and Fresenius Medical Care, Nephronomics emerged from stealth in 2025 with a focus on developing targeted therapies for cardio-kidney-metabolic diseases. The company has access to the My Reason® research program dataset sponsored by Fresenius Medical Care, which includes biospecimens and clinical information from thousands of patients with kidney disease.

Nephronomics’ technology platform is built around the Nephronomics Atlas, a large-scale clinical and genomic database designed to connect whole genome sequencing data with longitudinal medical records. The company says the database includes matched genomic and clinical information from more than 35,000 patients, providing researchers with a foundation for identifying biological patterns and potential therapeutic opportunities.

The company’s platform applies artificial intelligence and machine learning techniques to analyze complex healthcare datasets, including electronic medical records, multi-omics data, and imaging information. By combining these sources, Nephronomics aims to identify clinically meaningful disease subtypes and uncover relationships between genetic factors and disease progression.

Kidney disease remains a major global healthcare challenge, particularly as chronic kidney conditions often interact with cardiovascular and metabolic disorders. Nephronomics is focused on redefining traditional approaches to kidney disease by identifying molecular drivers and patient-specific characteristics that could lead to more targeted therapies. The company’s approach is based on the idea that improved classification of disease biology can enable more precise treatment strategies.

The company’s founders bring experience across nephrology, human genomics, and therapeutic development. Nephronomics’ leadership team includes Founder and Acting CEO Jan Walter, PhD; Founder and Chief Scientific Officer Deniz Kural, PhD; Founder and Acting Chief Medical Officer Benjamin Hippen, MD; and Founder and Board Member James Sietstra. The team is supported by experts in data science, bioinformatics, medicine, and scientific research.

The investment from CerraCap Ventures will help Nephronomics advance its AI-driven discovery platform and expand its capabilities in precision medicine. The company plans to continue developing computational models that can analyze large-scale healthcare datasets and generate insights for pharmaceutical research, clinical applications, and future therapeutic development.

Nephronomics’ work comes as pharmaceutical companies and healthcare researchers increasingly turn to artificial intelligence and large biological datasets to accelerate drug discovery. Traditional approaches to developing treatments can require years of research and extensive clinical testing, while AI-enabled platforms are increasingly being explored as tools for identifying new biological relationships and potential treatment pathways.

By combining access to extensive renal disease data with artificial intelligence capabilities, Nephronomics aims to create a new model for understanding kidney disease and related health conditions. The company’s platform is designed to help researchers move beyond broad disease categories and identify more precise patient groups that may respond differently to specific therapies.

The company’s investment from CerraCap Ventures marks an important step in its efforts to scale its technology and advance its precision medicine strategy. As healthcare systems continue to seek more personalized approaches to treating complex diseases, Nephronomics is positioning itself at the intersection of artificial intelligence, genomics, and therapeutic innovation.

With support from CerraCap Ventures and its collaboration with Fresenius Medical Care, Nephronomics plans to continue developing its AI-powered platform and expanding its role in kidney disease research. The company’s goal is to leverage data and computational biology to improve understanding of cardio-kidney-metabolic diseases and support the discovery of more targeted treatment options.

Related Articles